TriMas holds EPS outlook at $1.60–$1.70 and raises sales growth forecast to 4%–6%
Key Facts
On October 29, TriMas reaffirmed its forecast for adjusted diluted earnings per share from continuing operations of $1.60 to $1.70 for fiscal 2026 and raised its annual sales growth outlook to 4%–6% across its Packaging and Specialty Products businesses. In July, the company had announced an EPS range of $1.60 to $1.70, after an earlier forecast of $1.50 to $1.70, raising the lower end while keeping the upper end unchanged. In its latest update, it raised its sales growth range from 3%–6% to 4%–6%. The company also said it expects adjusted operating margin to expand by about 250 basis points during the year. The guidance combines sales growth with expected margin improvement, while production challenges in one of the company’s segments remain under review.
TriMas reported net sales of $178.7 million in the third quarter of 2026, up 7.7% year over year from $166.0 million in the same period of 2025. The company attributed the increase to organic growth in Packaging and Specialty Products and a favorable foreign currency translation effect. Adjusted diluted EPS from continuing operations was $0.50, compared with $0.17 a year earlier, an annual increase of 194.1%. The company linked the higher earnings primarily to interest income on cash, cost reductions and a lower share count following repurchases. The quarterly results provide a basis for the full-year outlook, while the earnings increase remains influenced by financing and operating factors as well as sales growth.
In the Packaging segment, third-quarter sales were $147.6 million, up 8.8% from the same period a year earlier. Growth spanned beauty and personal care, food and beverage, life sciences and industrial applications markets. Specialty Products reported sales of $31.2 million, up 2.7% year over year. But the segment’s operating profit and margin declined, as price increases did not offset higher raw material costs, alongside continued temporary manufacturing inefficiencies. The divergence between the two segments shows that sales growth alone did not translate into an equal improvement in profitability during the quarter.
Chief Executive Thomas Snyder said third-quarter results “did not yet reflect the full benefits of these actions,” citing continued effects from temporary productivity challenges at the Norris Cylinder plant. In February, the company said implemented cost-reduction initiatives were expected to generate annual savings of $15 million. In the second quarter, adjusted operating profit rose 29.1% to $14.9 million from $11.5 million a year earlier, which the company attributed to the execution of cost-reduction initiatives and a streamlined structure. Snyder said at the time that profitability and margins improved despite a changing market environment, driven by cost-cutting actions and operational improvements. The 2026 margin expansion outlook follows these measures, with the company acknowledging that production challenges continue to limit their full impact.
Separately from the Rapak sale agreement, TriMas completed the sale of its aerospace segment, and Snyder said the transaction strengthened the company’s financial flexibility. He added that net proceeds would be used to support organic growth investments, pursue strategically aligned acquisition opportunities and repurchase shares. Rapak, a provider of flexible bag-in-box packaging, dispensing and liquid filling solutions, was covered by a sale agreement signed by the company in October 2026. Closing was expected in November, meaning the sale had not been completed when the outlook was announced. The pending transaction therefore remains a later development in the company’s portfolio, while current sales guidance covers Packaging and Specialty Products combined.
The company’s fourth-quarter assumptions include interest income of about $10 million, with no significant change in interest rates or redeployment of cash proceeds during the remainder of the year. This means assumed interest income is one element of the annual outlook, alongside the effects of cost reductions and share repurchases on EPS. On October 22, TriMas announced a quarterly cash dividend of $0.04 per share, payable on November 12 to shareholders of record on a date set by the company. The dividend payment date falls in the same month in which the company expected the Rapak sale agreement to close. Near-term milestones therefore include the dividend payment and completion of the pending transaction, while the company left its annual EPS range unchanged in its October 29 announcement.